These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12605622)

  • 21. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses.
    Ornstova E; Sebestianova M; Mlcoch T; Lamblova K; Dolezal T
    Value Health Reg Issues; 2018 Sep; 16():92-98. PubMed ID: 30316030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the drug formulary and the purchasing process at a Moroccan university medical center.
    Lachhab Z; Serragui S; Hassar M; Cherrah Y; Errougani A; Ahid S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):415-421. PubMed ID: 29781758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug cost management in pharmacy management based on pharmacoeconomics: Antimicrobial treatment cases.
    Liu S; He L; Sun L; Wang Y
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1069-1073. PubMed ID: 28671083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacoeconomics].
    Shiragami M
    Yakugaku Zasshi; 2003 Mar; 123(3):133-42. PubMed ID: 12693013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulary development at Regence BlueShield--a formula for success.
    Fullerton DS; Atherly DS
    Value Health; 2002; 5(4):297-300. PubMed ID: 12102692
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Pharmacoeconomic Evaluation Process in Ireland.
    McCullagh L; Barry M
    Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics.
    Hughes DA
    Br J Clin Pharmacol; 2012 Jun; 73(6):968-72. PubMed ID: 22360714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insurance against drug costs--a progress report.
    WILKINSON WA
    Am J Public Health Nations Health; 1960 May; 50(5):670-4. PubMed ID: 13844765
    [No Abstract]   [Full Text] [Related]  

  • 35. [Guidelines for economic evaluation of pharmaceuticals in Korea].
    Bae EY
    J Prev Med Public Health; 2008 Mar; 41(2):80-3. PubMed ID: 18385547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective.
    Thomas N
    Pharmacoeconomics; 1996; 9 Suppl 1():9-15. PubMed ID: 10160115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating pharmacoeconomic principles into hospital pharmacy practice.
    Gouveia WA; Bungay KM
    Top Hosp Pharm Manage; 1994 Jan; 13(4):31-7. PubMed ID: 10130681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics?
    Goldman MP; Nair R
    Cleve Clin J Med; 2007 Aug; 74 Suppl 4():S38-47. PubMed ID: 17847177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic constraints and prescribing patterns in New Zealand.
    Kellaway GS
    Pharmacoeconomics; 1992 Sep; 2(3):189-97. PubMed ID: 10147009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.